Pulmonary embolism complicated the course of anti-N-methyl-D aspartate receptor encephalitis in a pediatric intensive care unit setting: a case report

ABSTRACT Introduction Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, an autoimmune neurological disorder resultant from the autoantibodies directed to the NR1 subunit of the NMDAR, is mainly characterized by neuropsychiatric symptoms, including behavior changes, paranoia, delusions, epileptic seizures, movement disorders, aphasia, insomnia, dysautonomia, and altered consciousness. Pulmonary embolism (PE) presents with pleuritic chest pain, hemoptysis, and respiratory distress by obstruction of the pulmonary circulation. Unlike adults, pediatric PE usually related to obvious risk factors, including central venous line, malignancy, lupus erythematosus, renal disease, congenital thrombophilia, surgery, and major trauma. Besides, PE has rarely been encountered in adult patients with anti-NMDAR encephalitis even in the absence of these risk factors. Case presentation A 16-year-old male patient, with acute psychosis, epileptic seizure, and altered consciousness, was diagnosed as having anti-NMDAR encephalitis and treated by intravenous immunoglobulin and high-dose pulse intravenous methylprednisolone. During follow-up, on the 11th day of hospitalization, the disease course was complicated by the occurrence of pulmonary embolism, presenting with acute onset respiratory distress and the need for supplementary oxygen treatment. PE improved with low-molecular-weight heparin treatment. Conclusion Pulmonary embolism should be kept in mind as a possible cause of respiratory insufficiency in pediatric anti-NMDAR encephalitis patients along with altered consciousness, breathing instability, hypersalivation, status epilepticus or dystonia, and their treatment.

[1]  Li Jiang,et al.  Seizure Characteristics, Outcome, and Risk of Epilepsy in Pediatric Anti-N-Methyl-d-Aspartate Receptor Encephalitis. , 2019, Pediatric neurology.

[2]  J. Zhao,et al.  Coexistence of Autoimmune Encephalitis and Other Systemic Autoimmune Diseases , 2019, Front. Neurol..

[3]  Massimiliano Valeriani,et al.  Relapse risk factors in anti‐N‐methyl‐D‐aspartate receptor encephalitis , 2019, Developmental medicine and child neurology.

[4]  M. Lydolph,et al.  Pediatric autoimmune encephalitis in Denmark during 2011-17: A nationwide multicenter population-based cohort study. , 2019, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[5]  M. Veeravigrom,et al.  Clinical manifestations, treatment outcomes, and prognostic factors of pediatric anti-NMDAR encephalitis in tertiary care hospitals: A multicenter retrospective/prospective cohort study , 2019, Brain and Development.

[6]  M. Sprengers,et al.  EBV-NMDA double positive encephalitis in an immunocompromised patient , 2019, Journal of the Neurological Sciences.

[7]  Mayara de Rezende Machado,et al.  Clinical variability of children with anti-N-methyl-d-aspartate receptor encephalitis in southern Brazil: a cases series and review of the literature , 2018, Neurological Sciences.

[8]  M. Rajpurkar,et al.  Pulmonary Embolism in Children. , 2018, Pediatric clinics of North America.

[9]  V. Wong,et al.  Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong , 2018, Brain and Development.

[10]  B. Boeve,et al.  Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis , 2018, Annals of neurology.

[11]  B. Anlar,et al.  Clinical presentation of anti-N-methyl-d-aspartate receptor and anti-voltage-gated potassium channel complex antibodies in children: A series of 24 cases. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[12]  Q. Lu,et al.  Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes , 2017, Journal of Neuroimmunology.

[13]  K. Kaida,et al.  Rituximab therapy and clinical management in anti-NMDA receptor antibody encephalitis refractory to first-line immunotherapy: Japanese case series , 2017, Journal of the Neurological Sciences.

[14]  C. Juan,et al.  Anti-N-Methyl-D-Aspartate-Receptor Encephalitis Complicated With Antiphospholipid Syndrome and Cerebral Venous Thrombosis. , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[15]  M. Steinschneider,et al.  Extended Clinical Spectrum of Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Children: A Case Series. , 2017, Pediatric neurology.

[16]  E. Amankwah,et al.  Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics , 2017, Thrombosis and Haemostasis.

[17]  D. Prabhakar,et al.  Neuropsychiatric Presentation of Anti-N-Methyl-D-Aspartate Receptor Encephalitis With Comorbid Sinus Venous Thrombosis. , 2016, The primary care companion for CNS disorders.

[18]  K. Chu,et al.  Frequent rhabdomyolysis in anti-NMDA receptor encephalitis , 2016, Journal of Neuroimmunology.

[19]  E. Oguni,et al.  Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis. , 2016, JAMA neurology.

[20]  A. Vincent,et al.  N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children , 2015, Archives of Disease in Childhood.

[21]  F. Rosendaal,et al.  The contribution of immobility risk factors to the incidence of venous thrombosis in an older population , 2014, Journal of thrombosis and haemostasis : JTH.

[22]  阪本 光 Details of treatment-related difficulties in men with anti-N-methyl D-aspartate receptor encephalitis , 2014 .

[23]  J. Dalmau,et al.  Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. , 2013, The Journal of pediatrics.

[24]  L. Honig,et al.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study , 2013, The Lancet Neurology.

[25]  L. Honig,et al.  Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study , 2013 .

[26]  J. Schieveld,et al.  Anti-NMDAR encephalitis: a new, severe and challenging enduring entity , 2013, European Child & Adolescent Psychiatry.

[27]  S. Kusunoki,et al.  Details of Treatment-Related Difficulties in Men with Anti-N-Methyl-d-Aspartate Receptor Encephalitis , 2012, European Neurology.

[28]  C. Lucchinetti,et al.  N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. , 2011, Archives of neurology.

[29]  A. Jacob,et al.  N-methyl D-aspartate receptor encephalitis: A new addition to the spectrum of autoimmune encephalitis , 2011, Annals of Indian Academy of Neurology.

[30]  J. Dalmau,et al.  Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. , 2010, Archives of neurology.

[31]  M. Rosenfeld,et al.  Anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescents , 2009, Annals of neurology.

[32]  A. Hida,et al.  RESPONSE OF ANTI-NMDA RECEPTOR ENCEPHALITIS WITHOUT TUMOR TO IMMUNOTHERAPY INCLUDING RITUXIMAB , 2008, Neurology.

[33]  Xiaoyu Peng,et al.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies , 2008, The Lancet Neurology.

[34]  Josep Dalmau,et al.  Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma , 2007, Annals of neurology.